This trial is evaluating whether Remimazolam will improve 1 primary outcome and 14 secondary outcomes in patients with ALL, Pediatric. Measurement will happen over the course of 2 hours.
This trial requires 100 total participants across 1 different treatment group
This trial involves a single treatment. Remimazolam is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 & 3 and have had some early promising results.
"All and pediatric, in children and adolescents, are not associated with any single factor, but a multi-cascading process composed of genetic vulnerability, environmental factors, and psychological factors are associated with the disease. Moreover, children and adolescents with all have a more severe form of the disease than adults." - Anonymous Online Contributor
"There is ample evidence for the effective use of medications in treating all forms of depression. Clinicians should be aware of the evidence, given the limitations of medications and the growing use of newer agents such as serotonin-norepinephrine reuptake inhibitors. In addition to the limitations of medications, many patients with depression also do not respond to medications. Therefore, the question arises of whether alternative therapies could play an important role in depression treatment." - Anonymous Online Contributor
"Given the growing numbers of pediatric and adolescent patients with cancer, there is a need for a strong medical education to support the management of children and young people through survivorship." - Anonymous Online Contributor
"A significant number of infants (approximately 7.9 million a year) receive one or more vaccines during their first year of life and are at risk for serious complications. These are associated with many healthcare resources (medical care, hospital admissions, ICUs, and inpatient care). The potential for a large number of serious infections may reduce the utility and cost-effectiveness of vaccines during infancy." - Anonymous Online Contributor
"Children are particularly vulnerable to sedative effects of benzodiazepines and this drug has been known to occur in a significant proportion of patients in pediatric wards. Thus children are a particularly exposed group of persons after taking a dose of remimazolam and it is advisable to restrict use of this medication to children." - Anonymous Online Contributor
"Each cancer needs a particular treatment approach, and individual results vary considerably. However, when the specific disease and needs are taken into account, some cancer patients can and do be cured. To the extent possible, all patients would benefit from proven approaches. The cure rate needs to increase and the treatment approach improved." - Anonymous Online Contributor
"The signs and symptoms of pneumonia in children and adolescents are similar to those seen in adults. The most common presenting symptoms in children are respiratory symptoms, such as fever and cough. Fever is often more severe and is typically accompanied by other symptoms of respiratory illness, such as increased respiratory rate, decreased breathing room, altered breathing sounds, an increased rate of breathing and the presence of wheezing. Children with pneumonia often develop chest pain in addition to the respiratory symptoms. A child with pleuritic symptoms or pneumonia with an abdominal distention should be evaluated with suspicion for the cause of these symptoms. Children with pleuritic symptoms should be evaluated by a doctor for the presence of pneumonia since pleuritic pain can be caused by the inflammatory response to pneumonia." - Anonymous Online Contributor
"Severe gastrointestinal or pancreatic disease in children may require exploratory laparotomy to control gastrointestinal symptoms to facilitate an endoscopy and biopsy. Laparotomy is associated with an increased risk of serious complications, although the risk is minimal when performed by a well-trained surgeon. However, the impact of laparotomy on hospital charges, time off from school, and quality of life is difficult to evaluate. The most reliable predictor of serious complication is a high BMI in the absence of severe comorbidities in children." - Anonymous Online Contributor
"No significant difference between the effect of remimazolam and a placebo was found. Remimazolam was not more effective than a placebo in lowering anxiety and insomnia in pediatric patients. However further studies examining individual patient needs are essential to better understand the need for benzodiazepine treatment." - Anonymous Online Contributor
"Oral remimazolam for the treatment of anxiety and insomnia is effective and well tolerated and offers a range of tolerability levels that may be tailored to individual patient preferences. The extended release formulation in pediatric patients has been well tolerated with an optimal pharmacokinetic profile. Both of these observations have recently been confirmed by a placebo-controlled clinical trial of remimazolam in adolescents with the diagnostic test: Sleep Disorder and Associated Traumatic Stress in Children (SOLIDS). Future studies aiming to refine and extend these observations regarding the expanded release formulation as a treatment of anxiety and insomnia in children are currently being carried out by SOLIDS." - Anonymous Online Contributor
"Current PPI trials are most prevalent in adults. It is essential to educate the public, especially children and physicians, to assure that all ages are evaluated in phase 2- or phase 3-standard clinical trials for PPI treatments." - Anonymous Online Contributor
"While many of the studies have been conducted before the publication of the latest Cochrane review, there is a large amount of research still needed, especially since clinicians are beginning to make more accurate diagnoses. A study in New Zealand for pediatric anxiety disorder found that [all, pediatric anxiety disorder symptoms occurred in 25% of children with anxiety, compared with 17.4% for all anxiety disorders] and that [in the United Kingdom, pediatric anxiety disorder symptoms occurred in 11% of children with anxiety, compared with 9.4% for all anxiety disorders] [Cameron, D., et al. (2005) Clin Pediatr Psychol. 17, 826-834 ((online)]." - Anonymous Online Contributor